


Amendments to the Claims

This listing of the claims will replace all prior versions, and listings, of claims in the present Application.

Listing of Claims

1. (Canceled)
2. (Currently amended) A compound of the Formula II:



II

wherein:

X is C₁₋₁₀ alkylene or C₂₋₁₀ alkenylene;

R_{A1} and R_{B1} are each ~~independently selected from the group consisting of:~~

~~hydrogen,~~

~~halogen,~~

~~alkyl,~~

~~alkenyl,~~

~~alkoxy,~~

~~alkylthio, and~~

~~N(R₉)₂;~~

~~or when taken together, R_{A1} and R_{B1} to form a fused aryl ring or heteroaryl ring containing one heteroatom selected from the group consisting of N and S, wherein the aryl or heteroaryl ring is unsubstituted or substituted by one or more R groups, or substituted by one R₃ group, or substituted by one R₃ group and one R group;~~

~~or when taken together, R_{A1} and R_{B1} form a fused 5 to 7 membered saturated ring, optionally containing one heteroatom selected from the group consisting of N and S, and unsubstituted or substituted by one or more R groups;~~

R is selected from the group consisting of:


halogen,
hydroxy,
alkyl,
alkenyl,
haloalkyl,
alkoxy,
alkylthio, and
-N(R₉)₂;

R₃ is selected from the group consisting of:


-Z-R₄,
-Z-X'-R₄,
-Z-X'-Y-R₄, and
~~-Z-X'-Y-X'-Y-R₄, and~~
-Z-X'-R₅;

Y' is selected from the group consisting of:

a bond,
-C(O)-,
-C(S)-,
-S(O)₂-,
-S(O)₂-N(R₈)-,



-C(O)-O-,
-C(O)-N(R₈)-,
-C(S)-N(R₈)-,

$$-\text{C}(\text{O})-\text{N}(\text{R}_8)-\text{S}(\text{O})_2-$$
$$-\text{C}(\text{O})-\text{N}(\text{R}_8)-\text{C}(\text{O})-$$
$$-\text{C}(\text{S})-\text{N}(\text{R}_8)-\text{C}(\text{O})-$$


-C(O)-C(O)-,

-C(O)-C(O)-O-, and

$$-\text{C}(=\text{NH})-\text{N}(\text{R}_8)-;$$

R_1 is selected from the group consisting of:

-R₄,

$$-X'-R_4,$$
$$-X'-Y-R_4,$$

-X'-Y-X'-Y-R₄, and

$$-X'-R_5[[,]];$$
 ~~$X''-O-NR_{1a}-Y'-R_{1b}$, and~~
$$\text{---X''---O---N=C(R}_4\text{'')(R}_4\text{'')};$$

$R_{1a}, R_{1b}, R_1', R_1'', R_2[[,]]$ and R_{2a} are independently selected from the group consisting of:

hydrogen,

alkyl,

alkenyl,

aryl,

arylalkylenyl,

heteroaryl,

heteroarylalkylenyl,

heterocyclyl,


heterocyclalkylenyl, and

alkyl, alkenyl, aryl, arylalkylenyl, heteroaryl, heteroarylalkylenyl, heterocyclyl, or


heterocyclalkylenyl, substituted by one or more substituents selected from the group consisting of:

hydroxy,
alkyl,
haloalkyl,
hydroxyalkyl,
alkoxy,
dialkylamino,
-S(O)₀₋₂-alkyl,
-S(O)₀₋₂-aryl,
-NH-S(O)₂-alkyl,
-NH-S(O)₂-aryl,
haloalkoxy,
halogen,
cyano,
nitro,
aryl,
heteroaryl,
heterocyclcyl,
aryloxy,
arylalkyleneoxy,
-C(O)-O-alkyl,
-C(O)-N(R₈)₂,
-N(R₈)-C(O)-alkyl,
-O-(CO)-alkyl, and
-C(O)-alkyl;


or ~~R_{1a} and R_{1b} and/or~~ R₂ and R_{2a} together with the nitrogen atom and Y' to which they are bonded can join to form a ring selected from the group consisting of:



~~or R_1' and R_1'' can join together to form a ring system selected from the group consisting of:~~



~~wherein the total number of atoms in the ring is 4 to 9, and~~



~~wherein the total number of atoms in the ring is 4 to 9;~~

~~R_6 and R_4 are independently selected from the group consisting of hydrogen, halogen, hydroxy, alkyl, alkenyl, aryl, haloalkyl, alkoxy, alkylthio, and $N(R_9)_2$; or R_6 and R_4 can join to form a fused aryl ring or fused 5-10 membered heteroaryl ring containing one to four heteroatoms;~~

X' is selected from the group consisting of alkylene, alkenylene, alkynylene, arylene, heteroarylene, and heterocyclylene wherein the alkylene, alkenylene, and alkynylene groups can be optionally interrupted or terminated by arylene, heteroarylene or heterocyclylene and optionally interrupted by one or more -O- groups;

~~X'' is $CH(R_{13})$ alkylene or $CH(R_{13})$ alkenylene, wherein the alkylene and alkenylene are optionally interrupted by one or more -O- groups;~~

Y is selected from the group consisting of:

-S(O)₀₋₂-,

-S(O)₂-N(R₈)-,

-C(R₆)-,

-C(R₆)-O-,

-O-C(R₆)-,


-O-C(O)-O-,

-N(R₈)-Q-,

-C(R₆)-N(R₈)-,

-O-C(R₆)-N(R₈)-,


-C(R₆)-N(OR₉)-,



Z is a bond or -O-;

R₄ is selected from the group consisting of hydrogen, alkyl, alkenyl, alkynyl, aryl, arylalkylenyl, aryloxyalkylenyl, alkylarylenyl, heteroaryl, heteroarylalkylenyl, heteroaryloxyalkylenyl, alkylheteroarylenyl, and heterocyclyl wherein the alkyl, alkenyl, alkynyl, aryl, arylalkylenyl, aryloxyalkylenyl, alkylarylenyl, heteroaryl, heteroarylalkylenyl, heteroaryloxyalkylenyl, alkylheteroarylenyl, and heterocyclyl groups can be unsubstituted or substituted by one or more substituents independently selected from the group consisting of alkyl, alkoxy, hydroxyalkyl, haloalkyl, haloalkoxy, halogen, nitro, hydroxy, mercapto, cyano, aryl, aryloxy, arylalkyleneoxy, heteroaryl, heteroaryloxy, heteroarylalkyleneoxy, heterocyclyl, amino, alkylamino, dialkylamino, (dialkylamino)alkyleneoxy, and in the case of alkyl, alkenyl, alkynyl, and heterocyclyl, oxo;

R₅ is selected from the group consisting of:



R₆ is selected from the group consisting of =O and =S;

R₇ is C₂₋₇ alkylene;

R₈ is selected from the group consisting of hydrogen, C₁₋₁₀ alkyl, C₂₋₁₀ alkenyl, C₁₋₁₀ alkoxy-C₁₋₁₀ alkylenyl, and aryl-C₁₋₁₀ alkylenyl;

R₉ is selected from the group consisting of hydrogen and alkyl;

R₁₀ is C₃₋₈ alkylene;

~~R₁₁ is C₁₋₆ alkylene or C₂₋₆ alkenylene, wherein the alkylene or alkenylene is optionally interrupted by one heteroatom;~~

~~R₁₂ is selected from the group consisting of a bond, C₁₋₅ alkylene, and C₂₋₅ alkenylene, wherein the alkylene or alkenylene is optionally interrupted by one heteroatom;~~

~~R₁₃ is selected from the group consisting of hydrogen and alkyl which may be optionally interrupted by one or more O groups;~~

A is selected from the group consisting of -CH₂-, -O-, -C(O)-, -S(O)₀₋₂-, and -N(R₄)-

~~A' is selected from the group consisting of O, S(O)₀₋₂, N(Q R₄), and CH₂;~~

Q is selected from the group consisting of a bond, -C(R₆)-, -C(R₆)-C(R₆)-, -S(O)₂-, -C(R₆)-N(R₈)-W-, -S(O)₂-N(R₈)-, -C(R₆)-O-, and -C(R₆)-N(OR₉)-


V is selected from the group consisting of -C(R₆)-, -O-C(R₆)-, -N(R₈)-C(R₆)-, and -S(O)₂-;

W is selected from the group consisting of a bond, -C(O)-, and -S(O)₂-; and

a and b are independently integers from 1 to 6 with the proviso that a+b is ≤ 7; or a pharmaceutically acceptable salt thereof.

3. (Canceled)

4. (Currently amended) [[A]] The compound of claim 2 of the Formula IIIa:



IIIa

wherein:

X is C₁₋₁₀ alkylene or C₂₋₁₀ alkenylene;

Y' is selected from the group consisting of:


a bond,

-C(O)-,

-C(S)-,

-S(O)₂-,

-S(O)₂-N(R₈)-,



-C(O)-O-,


-C(O)-N(R₈)-,

-C(S)-N(R₈)-,

-C(O)-N(R₈)-S(O)₂-,

-C(O)-N(R₈)-C(O)-,

-C(S)-N(R₈)-C(O)-,



-C(O)-C(O)-,

-C(O)-C(O)-O-, and

-C(=NH)-N(R₈)-;

R is selected from the group consisting of:

halogen,
hydroxy,
alkyl,
alkenyl,
haloalkyl,
alkoxy,
alkylthio, and
-N(R₉)₂;

R₁ is selected from the group consisting of:


-R₄,
-X'-R₄,
-X'-Y-R₄,
-X'-Y-X'-Y-R₄, and
-X'-R₅[[,]];
~~-X''-O-NR_{1a}-Y'-R_{1b}, and~~
~~-X''-O-N=C(R₁') (R₁'');~~

~~R_{1a}, R_{1b}, R₁', R₁'', R₂[[,]] and R_{2a}~~ are independently selected from the group consisting of:


hydrogen,
alkyl,
alkenyl,
aryl,
arylalkylenyl,
heteroaryl,
heteroarylalkylenyl,
heterocyclyl,
heterocyclylalkylenyl, and

alkyl, alkenyl, aryl, arylalkylenyl, heteroaryl, heteroarylalkylenyl, heterocyclyl, or
heterocyclylalkylenyl, substituted by one or more substituents selected from the group consisting of:

~~or R_1' and R_1'' can join together to form a ring system selected from the group consisting of:~~



~~wherein the total number of atoms in the ring is 4 to 9, and~~



~~wherein the total number of atoms in the ring is 4 to 9;~~

~~R_c and R_d are independently selected from the group consisting of hydrogen, halogen, hydroxy, alkyl, alkenyl, aryl, haloalkyl, alkoxy, alkylthio, and $N(R_9)_2$; or R_c and R_d can join to form a fused aryl ring or fused 5-10 membered heteroaryl ring containing one to four heteroatoms;~~

R_3 is selected from the group consisting of:

~~-Z- R_4 ,~~

~~-Z- X' - R_4 ,~~

~~-Z- X' -Y- R_4 , and~~

~~-Z-X-Y-X'-Y- R_4 , and~~

~~-Z- X' - R_5 ;~~

n is an integer from 0 to 4;

m is 0 or 1;

with the proviso that when m is 1, then n is 0 or 1;



X' is selected from the group consisting of alkylene, alkenylene, alkynylene, arylene, heteroarylene, and heterocyclylene wherein the alkylene, alkenylene, and alkynylene groups can be optionally interrupted or terminated by arylene, heteroarylene or heterocyclylene and optionally interrupted by one or more -O- groups;

~~X'' is $CH(R_{13})$ alkylene or $CH(R_{13})$ alkenylene, wherein the alkylene and alkenylene are optionally interrupted by one or more O groups;~~

Y is selected from the group consisting of:

~~-S(O)₀₋₂-,~~

~~-S(O)₂-N(R_8)-,~~




Z is a bond or -O-;

R₄ is selected from the group consisting of hydrogen, alkyl, alkenyl, alkynyl, aryl, arylalkylenyl, aryloxyalkylenyl, alkylarylenyl, heteroaryl, heteroarylalkylenyl, heteroaryloxyalkylenyl, alkylheteroarylenyl, and heterocyclyl wherein the alkyl, alkenyl, alkynyl, aryl, arylalkylenyl, aryloxyalkylenyl, alkylarylenyl, heteroaryl, heteroarylalkylenyl, heteroaryloxyalkylenyl, alkylheteroarylenyl, and heterocyclyl groups can be unsubstituted or substituted by one or more substituents independently selected from the group consisting of alkyl, alkoxy, hydroxyalkyl, haloalkyl, haloalkoxy, halogen, nitro, hydroxy, mercapto, cyano, aryl,

aryloxy, arylalkyleneoxy, heteroaryl, heteroaryloxy, heteroarylalkyleneoxy, heterocyclyl, amino, alkylamino, dialkylamino, (dialkylamino)alkyleneoxy, and in the case of alkyl, alkenyl, alkynyl, and heterocyclyl, oxo;

R_5 is selected from the group consisting of:



R₆ is selected from the group consisting of =O and =S;

R₇ is C₂₋₇ alkylene;

R₈ is selected from the group consisting of hydrogen, C₁₋₁₀ alkyl, C₂₋₁₀ alkenyl, C₁₋₁₀ alkoxy-C₁₋₁₀ alkylenyl, and aryl-C₁₋₁₀ alkylenyl;

R₉ is selected from the group consisting of hydrogen and alkyl;

R₁₀ is C₃₋₈ alkylene;

~~R₁₁ is C₁₋₆-alkylene or C₂₋₆-alkenylene, wherein the alkylene or alkenylene is optionally interrupted by one heteroatom;~~

~~R₁₂ is selected from the group consisting of a bond, C₁₋₅-alkylene, and C₂₋₅-alkenylene, wherein the alkylene or alkenylene is optionally interrupted by one heteroatom;~~

~~R₁₃ is selected from the group consisting of hydrogen and alkyl which may be optionally interrupted by one or more O groups;~~

A is selected from the group consisting of $-\text{CH}_2-$, $-\text{O}-$, $-\text{C}(\text{O})-$, $-\text{S}(\text{O})_{0-2}-$, and $-\text{N}(\text{R}_4)-$;

~~A' is selected from the group consisting of O, S(O)_{0.2}, N(QR₄), and CH₂;~~

Q is selected from the group consisting of a bond, -C(R₆)-, -C(R₆)-C(R₆)-, -S(O)₂-, -C(R₆)-N(R₈)-W-, -S(O)₂-N(R₈)-, -C(R₆)-O-, and -C(R₆)-N(OR₉)-;


V is selected from the group consisting of -C(R₆)-, -O-C(R₆)-, -N(R₈)-C(R₆)-, and -S(O)₂-;

W is selected from the group consisting of a bond, -C(O)-, and -S(O)₂-; and

a and b are independently integers from 1 to 6 with the proviso that $a+b$ is ≤ 7 ;

or a pharmaceutically acceptable salt thereof.

5. (Currently amended) [[A]] The compound of claim 2 of the Formula IIIa ~~IIIa~~:



wherein:

X is C₁₋₁₀ alkylene or C₂₋₁₀ alkenylene;

Y' is selected from the group consisting of:


a bond,

-C(O)-,

-C(S)-,

-S(O)₂-,

-S(O)₂-N(R₈)-,

-S(O)₂-N ,

-C(O)-O-,


-C(O)-N(R₈)-,

-C(S)-N(R₈)-,

-C(O)-N(R₈)-S(O)₂-,

-C(O)-N(R₈)-C(O)-,

-C(S)-N(R₈)-C(O)-,

-C(O)-N ,

-C(O)-C(O)-,

-C(O)-C(O)-O-, and

-C(=NH)-N(R₈)-;

R₂ and R_{2a} are independently selected from the group consisting of:

hydrogen,

alkyl,

alkenyl,

aryl,

arylalkylenyl,

heteroaryl,

heteroarylalkylenyl,

heterocyclyl,

heterocyclylalkylenyl, and

alkyl, alkenyl, aryl, arylalkylenyl, heteroaryl, heteroarylalkylenyl, heterocyclyl, or

heterocyclylalkylenyl, substituted by one or more substituents selected from the group consisting of:

hydroxy,

alkyl,

haloalkyl,

hydroxyalkyl,

alkoxy,

dialkylamino,

-S(O)₀₋₂-alkyl,

-S(O)₀₋₂-aryl,

-NH-S(O)₂-alkyl,

-NH-S(O)₂-aryl,

haloalkoxy,

halogen,

cyano,

nitro,

aryl,

heteroaryl,
heterocyclyl,
aryloxy,
arylalkyleneoxy,
-C(O)-O-alkyl,
-C(O)-N(R₈)₂,
-N(R₈)-C(O)-alkyl,
-O-(CO)-alkyl, and
-C(O)-alkyl;

~~R is selected from the group consisting of:~~




~~halogen,
hydroxy,
alkyl,
alkenyl,
haloalkyl,
alkoxy,
alkylthio, and
-N(R₉)₂;~~

R₁ is selected from the group consisting of:

-R₄,
-X'-R₄,
-X'-Y-R₄,
-X'-Y-X'-Y-R₄, and
-X'-R₅[[,]];
~~-X''-O-NH-Y'-R₄'~~, and
~~-X''-O-N=C(R₄')~~(R₄'');

~~R₃ is selected from the group consisting of:~~

~~-Z-R₄,
-Z-X'-R₄,~~



~~n is an integer from 0 to 4;~~





~~m is 0 or 1;~~


~~with the proviso that when m is 1, then n is 0 or 1;~~

X' is selected from the group consisting of alkylene, alkenylene, alkynylene, arylene, heteroarylene, and heterocyclylene wherein the alkylene, alkenylene, and alkynylene groups can be optionally interrupted or terminated by arylene, heteroarylene or heterocyclylene and optionally interrupted by one or more -O- groups;

~~X'' is CH(R₁₃)-alkylene or CH(R₁₃)-alkenylene;~~


Y is selected from the group consisting of:




~~Z is a bond or O:~~

R₄ is selected from the group consisting of hydrogen, alkyl, alkenyl, alkynyl, aryl, arylalkylenyl, aryloxyalkylenyl, alkylarylenyl, heteroaryl, heteroarylalkylenyl, heteroaryloxyalkylenyl, alkylheteroarylenyl, and heterocyclyl wherein the alkyl, alkenyl, alkynyl, aryl, arylalkylenyl, aryloxyalkylenyl, alkylarylenyl, heteroaryl, heteroarylalkylenyl, heteroaryloxyalkylenyl, alkylheteroarylenyl, and heterocyclyl groups can be unsubstituted or substituted by one or more substituents independently selected from the group consisting of alkyl, alkoxy, hydroxyalkyl, haloalkyl, haloalkoxy, halogen, nitro, hydroxy, mercapto, cyano, aryl, aryloxy, arylalkyleneoxy, heteroaryl, heteroaryloxy, heteroarylalkyleneoxy, heterocyclyl, amino, alkylamino, dialkylamino, (dialkylamino)alkyleneoxy, and in the case of alkyl, alkenyl, alkynyl, and heterocyclyl, oxo;


R₅ is selected from the group consisting of:



~~R₁' and R₁" are independently the same as R₂, or R₁' and R₁" can join together to form a ring system selected from the group consisting of:~~



~~wherein the total number of atoms in the ring is 4 to 9, and~~



~~wherein the total number of atoms in the ring is 4 to 9;~~

~~R₆ and R₄ are independently selected from the group consisting of hydrogen, halogen, hydroxy, alkyl, alkenyl, aryl, haloalkyl, alkoxy, alkylthio, and N(R₉)₂; or R₆ and R₄ can join to form a fused aryl ring or fused 5-10 membered heteroaryl ring containing one to four heteroatoms;~~

~~R₆ is selected from the group consisting of =O and =S;~~

~~R₇ is C₂₋₇ alkylene;~~

~~R₈ is selected from the group consisting of hydrogen, C₁₋₁₀ alkyl, C₂₋₁₀ alkenyl, C₁₋₁₀ alkoxy-C₁₋₁₀ alkylenyl, and aryl-C₁₋₁₀ alkylenyl;~~

~~R₉ is selected from the group consisting of hydrogen and alkyl;~~

~~R₁₀ is C₃₋₈ alkylene;~~

~~R₁₁ is C₁₋₆ alkylene or C₂₋₆ alkenylene, wherein the alkylene or alkenylene is optionally interrupted by one heteroatom;~~

~~R₁₂ is selected from the group consisting of a bond, C₁₋₅ alkylene, and C₂₋₅ alkenylene, wherein the alkylene or alkenylene is optionally interrupted by one heteroatom;~~

~~R₁₃ is selected from the group consisting of hydrogen and alkyl which may be optionally interrupted by one or more O groups;~~

~~A is selected from the group consisting of -CH₂-, -O-, -C(O)-, -S(O)₀₋₂-, and -N(R₄)-;~~

~~A' is selected from the group consisting of O, S(O)₀₋₂, N(Q R₄), and -CH₂;~~

~~Q is selected from the group consisting of a bond, -C(R₆)-, -C(R₆)-C(R₆)-, -S(O)₂-, -C(R₆)-N(R₈)-W-, -S(O)₂-N(R₈)-, -C(R₆)-O-, and -C(R₆)-N(OR₉)-;~~

~~V is selected from the group consisting of -C(R₆)-, -O-C(R₆)-, -N(R₈)-C(R₆)-, and -S(O)₂-; and~~

~~W is selected from the group consisting of a bond, -C(O)-, and -S(O)₂-; and~~

~~a and b are independently integers from 1 to 6 with the proviso that a+b is ≤ 7;~~


~~or a pharmaceutically acceptable salt thereof.~~

6.-13. (Canceled)


14. (Previously presented) The compound or salt of claim 4 wherein m and n are 0.

15.-18. (Canceled)


19. (Previously presented) The compound or salt of claim 2 wherein R_1 is selected from the group consisting of alkyl, arylalkylenyl, aryloxyalkylenyl, hydroxyalkyl, alkylsulfonylalkylenyl, $-X'-Y-R_4$, and $-X'-R_5$; wherein X' is alkylene; Y is $-N(R_8)-C(O)-$, $-N(R_8)-S(O)_2-$, $-N(R_8)-S(O)_2-N(R_8)-$, $-N(R_8)-C(O)-N(R_8)-$, $-N(R_8)-C(O)-N(R_8)-C(O)-$,



; R_4 is hydrogen, alkyl, alkenyl, aryl, or heteroaryl, wherein alkyl and alkenyl are optionally substituted by aryl or aryloxy and wherein aryl is optionally substituted by one or more substituents selected from the group consisting of alkyl, alkoxy, cyano, haloalkyl, and halogen; and R_5 is



20. (Previously presented) The compound or salt of claim 19 wherein R_1 is 2-methylpropyl, 2-hydroxy-2-methylpropyl, or $-X'-Y-R_4$; X' is ethylene, propylene, or butylene; Y is $-NH-C(O)-$, $-NH-S(O)_2-$, $-NH-S(O)_2-N(R_8)-$, $-NH-C(O)-N(R_8)-$, $-NH-C(O)-NH-C(O)-$, or



; and R_8 is hydrogen or methyl.


21. (Previously presented) The compound or salt of claim 2 wherein X is C_{1-4} alkylene.

22. (Previously presented) The compound or salt of claim 21 wherein X is methylene.

23. (Previously presented) The compound or salt of claim 2 wherein Y' is selected from

the group consisting of a bond, -C(O)-, -C(O)-O-, -S(O)₂-, -S(O)₂-N(R₈)-, -C(O)-N(R₈)-, -C(S)-

N(R₈)-, -C(O)-N(R₈)-C(O)-, and



24. (Previously presented) The compound or salt of claim 23 wherein Y' is selected from the group consisting of -C(O)-, -S(O)₂-, and -C(O)-N(R₈)-.

25. (Previously presented) The compound or salt of claim 2 wherein R₂ and R_{2a} are independently selected from the group consisting of: hydrogen, alkyl, alkenyl, aryl, arylalkylenyl, heteroaryl, heteroarylalkylenyl, heterocyclyl, heterocyclalkylenyl, and alkyl, alkenyl, aryl, arylalkylenyl, heteroaryl, heteroarylalkylenyl, heterocyclyl, or heterocyclalkylenyl, substituted by one or more substituents selected from the group consisting of: hydroxy, alkyl, haloalkyl, hydroxyalkyl, alkoxy, dialkylamino, -S(O)₀₋₂-alkyl, -S(O)₀₋₂-aryl, -NH-S(O)₂-alkyl, -NH-S(O)₂-aryl, haloalkoxy, halogen, cyano, nitro, aryl, heteroaryl, heterocyclyl, aryloxy, arylalkyleneoxy, -C(O)-O-alkyl, -C(O)-N(R₈)₂, -N(R₈)-C(O)-alkyl, -O-(CO)-alkyl, and -C(O)-alkyl.

26. (Previously presented) The compound or salt of claim 2 wherein R_{2a} is hydrogen.

27. (Previously presented) The compound or salt of claim 2 wherein R₂ and R_{2a} are independently selected from the group consisting of hydrogen, alkyl, alkenyl, aryl, heteroaryl, wherein the alkyl, alkenyl, aryl, and heteroaryl are each optionally substituted with one or more substituents selected from the group consisting of C₁₋₁₀ alkyl, aryl, heteroaryl, C₁₋₁₀ alkoxy, -O-C(O)-C₁₋₁₀ alkyl, -C(O)-O-C₁₋₁₀ alkyl, halogen, and cyano.

28. (Previously presented) The compound or salt of claim 2 wherein R₂ is alkyl or substituted alkyl, and R_{2a} is hydrogen.

29. (Previously presented) The compound or salt of claim 28 wherein R_2 is methyl or cyclopropyl, and R_{2a} is hydrogen.

30-34. (Canceled)


35. (Previously presented) A pharmaceutical composition comprising a therapeutically effective amount of a compound or salt of claim 2 in combination with a pharmaceutically acceptable carrier.

36. (Withdrawn) A method of inducing cytokine biosynthesis in an animal comprising administering an effective amount of a compound or salt of claim 2 to the animal.


37. (Withdrawn) A method of treating a viral disease in an animal in need thereof comprising administering a therapeutically effective amount of a compound or salt of claim 2 to the animal.

38. (Withdrawn) A method of treating a neoplastic disease in an animal in need thereof comprising administering a therapeutically effective amount of a compound or salt of claim 2 to the animal.


39. (Currently amended) The compound or salt of claim 4 or 5 wherein R_1 is selected from the group consisting of alkyl, arylalkylenyl, aryloxyalkylenyl, hydroxyalkyl, alkylsulfonylalkylenyl, $-X'-Y-R_4$, and $-X'-R_5$; wherein X' is alkylene; Y is $-N(R_8)-C(O)-$, $-N(R_8)-S(O)_2-$, $-N(R_8)-S(O)_2-N(R_8)-$, $-N(R_8)-C(O)-N(R_8)-$, $-N(R_8)-C(O)-N(R_8)-C(O)-$,



; and R_4 is hydrogen, alkyl, alkenyl, aryl, or heteroaryl, wherein alkyl and alkenyl are optionally substituted by aryl or aryloxy and wherein aryl is optionally substituted by one or more substituents selected from the group consisting of alkyl, alkoxy, cyano, haloalkyl, and halogen; and R_5 is



40. (Previously presented) The compound or salt of claim 39 wherein R₁ is 2-methylpropyl, 2-hydroxy-2-methylpropyl, or -X'-Y-R₄; X' is ethylene, propylene, or butylene; Y is -NH-C(O)-, -NH-S(O)₂-, -NH-S(O)₂-N(R₈)-, -NH-C(O)-N(R₈)-, -NH-C(O)-NH-C(O)-, or




; and R₈ is hydrogen or methyl.

41. (Currently amended) The compound or salt of claim 4 or 5 wherein X is C₁₋₄ alkylene.

42. (Previously presented) The compound or salt of claim 41 wherein X is methylene.

43. (Currently amended) The compound or salt of claim 4 or 5 wherein Y' is selected from the group consisting of a bond, -C(O)-, -C(O)-O-, -S(O)₂-, -S(O)₂-N(R₈)-, -C(O)-N(R₈)-, -C(S)-



N(R₈)-, -C(O)-N(R₈)-C(O)-, and

44. (Previously presented) The compound or salt of claim 43 wherein Y' is selected from the group consisting of -C(O)-, -S(O)₂-, and -C(O)-N(R₈)-.

45. (Currently amended) The compound or salt of claim 4 or 5 wherein R₂ and R_{2a} are independently selected from the group consisting of: hydrogen, alkyl, alkenyl, aryl, arylalkylenyl, heteroaryl, heteroarylalkylenyl, heterocyclyl, heterocyclylalkylenyl, and alkyl, alkenyl, aryl, arylalkylenyl, heteroaryl, heteroarylalkylenyl, heterocyclyl, or heterocyclylalkylenyl, substituted by one or more substituents selected from the group consisting of: hydroxy, alkyl, haloalkyl,

hydroxyalkyl, alkoxy, dialkylamino, -S(O)₀₋₂-alkyl, -S(O)₀₋₂-aryl, -NH-S(O)₂-alkyl, -NH-S(O)₂-aryl, haloalkoxy, halogen, cyano, nitro, aryl, heteroaryl, heterocyclyl, aryloxy, arylalkyleneoxy, -C(O)-O-alkyl, -C(O)-N(R₈)₂, -N(R₈)-C(O)-alkyl, -O-(CO)-alkyl, and -C(O)-alkyl.

46. (Currently amended) The compound or salt of claim 4 or 5 wherein R_{2a} is hydrogen.

47. (Currently amended) The compound or salt of claim 4 or 5 wherein R₂ and R_{2a} are independently selected from the group consisting of hydrogen, alkyl, alkenyl, aryl, heteroaryl, wherein the alkyl, alkenyl, aryl, and heteroaryl are each optionally substituted with one or more substituents selected from the group consisting of C₁₋₁₀ alkyl, aryl, heteroaryl, C₁₋₁₀ alkoxy, -O-C(O)-C₁₋₁₀ alkyl, -C(O)-O-C₁₋₁₀ alkyl, halogen, and cyano.

48. (Currently amended) The compound or salt of claim 4 or 5 wherein R₂ is alkyl or substituted alkyl, and R_{2a} is hydrogen.

49. (Previously presented) The compound or salt of claim 48 wherein R₂ is methyl or cyclopropyl, and R_{2a} is hydrogen.

50.-64. (Canceled)

65. (Currently amended) A pharmaceutical composition comprising a therapeutically effective amount of a compound or salt of claim 4 or 5 in combination with a pharmaceutically acceptable carrier.

66. (Currently amended) A method of inducing cytokine biosynthesis in an animal comprising administering an effective amount of a compound or salt of claim 4 or 5 to the animal.

67.-72. (Canceled)